文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

吸入依前列醇与俯卧位通气对插管COVID-19难治性低氧血症患者的疗效

Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia.
PubMed 文献 · Crit Care Explor · 2020-12-16
一句话结论在COVID-19机械通气难治性低氧血症患者中,吸入依前列醇联合俯卧位通气较单用任一措施更改善氧合,联合应答者死亡率更低。

该回顾性研究纳入43例接受有创通气的成人COVID-19难治性低氧血症患者,评估吸入依前列醇与俯卧位通气单独及联合应用的效果。结果显示,单独俯卧位或单独吸入依前列醇前后PaO2/FiO2无显著差异,但联合应用后PaO2/FiO2从84.0 mmHg升至124.7 mmHg(p<0.001),同时启动的14例患者从78.9升至150.2 mmHg(p=0.005)。27例(63%)联合治疗氧合改善>20%,应答者死亡率显著低于无应答者(52% vs 81%,p=0.025)。结论需随机前瞻性试验验证。

要点

  • 联合吸入依前列醇与俯卧位通气后PaO2/FiO2从84.0 mmHg升至124.7 mmHg(p<0.001),单独使用任一措施无显著改善。
  • 同时启动吸入依前列醇和俯卧位的14例患者PaO2/FiO2从78.9 mmHg升至150.2 mmHg(p=0.005)。
  • 27例(63%)联合治疗氧合改善>20%,应答者死亡率52%显著低于无应答者81%(p=0.025)。
  • 纳入标准为有创通气期间接受吸入依前列醇和俯卧位通气的成人COVID-19患者;PaO2/FiO2>150 mmHg者排除。
  • 该研究为回顾性设计,样本量43例,结论需随机前瞻性临床试验验证。

适用人群与场景

  • 成人COVID-19有创机械通气患者,接受吸入依前列醇和俯卧位通气。
  • 排除:吸入依前列醇在外院启动、俯卧位终止后启动、ECMO或心肺复苏期间启动、PaO2/FiO2>150 mmHg者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 对COVID-19有创通气难治性低氧血症患者,可考虑联合吸入依前列醇与俯卧位通气;原文未提供依前列醇剂量、给药频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性研究,43例成人COVID-19有创通气患者,单中心学术医院成人ICU。
  • 单独俯卧位或单独吸入依前列醇前后PaO2/FiO2无显著差异(89.1 vs 97.6 mmHg,p=0.393)。
  • 联合吸入依前列醇与俯卧位后PaO2/FiO2从84.0升至124.7 mmHg(p<0.001)。
  • 同时启动联合治疗的14例患者PaO2/FiO2从78.9升至150.2 mmHg(p=0.005)。
  • 27例(63%)联合治疗氧合改善>20%;应答者死亡率52% vs 无应答者81%(p=0.025)。

证据类型、等级与局限

  • 回顾性研究,单中心,样本量43例,开放标签设计,需随机前瞻性试验验证。

对床旁实践的改变

  • 在COVID-19有创通气难治性低氧血症患者中,联合吸入依前列醇与俯卧位通气可能改善氧合,应答者死亡率更低;但证据来自回顾性单中心研究,不能作为常规推荐,需前瞻性验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the effects of inhaled epoprostenol and prone positioning, individually and in combination in mechanically ventilated patients with coronavirus disease 2019 and refractory hypoxemia.

DESIGN: Retrospective study.

SETTING: Academic hospital adult ICUs.

PATIENTS: Adult patients who received inhaled epoprostenol and prone positioning during invasive ventilation were enrolled. Patients were excluded if inhaled epoprostenol was initiated: 1) at an outside hospital, 2) after prone positioning was terminated, 3) during extracorporeal membrane oxygenation or cardiopulmonary resuscitation, and 4) with Pao2/Fio2 greater than 150 mm Hg.

INTERVENTIONS: Inhaled epoprostenol and prone positioning.

RESULTS: Of the 43 eligible patients, 22 and seven received prone positioning and inhaled epoprostenol alone, respectively, prior to their use in combination, Pao2/Fio2 was not different pre- and post-prone positioning or inhaled epoprostenol individually (89.1 [30.6] vs 97.6 [30.2] mm Hg; p = 0.393) but improved after the combined use of inhaled epoprostenol and prone positioning (84.0 [25.6] vs 124.7 [62.7] mm Hg; p < 0.001). While inhaled epoprostenol and prone positioning were instituted simultaneously in 14 patients, Pao2/Fio2 was significantly improved (78.9 [27.0] vs 150.2 [56.2] mm Hg, p = 0.005) with the combination. Twenty-seven patients (63%) had greater than 20% improvement in oxygenation with the combination of inhaled epoprostenol and prone positioning, and responders had lower mortality than nonresponders (52 vs 81%; p = 0.025).

CONCLUSIONS: In critically ill, mechanically ventilated patients with coronavirus disease 2019 who had refractory hypoxemia, oxygenation improved to a greater extent with combined use of inhaled epoprostenol and prone positioning than with each treatment individually. A higher proportion of responders to combined inhaled epoprostenol and prone positioning survived compared with nonresponders. These findings need to be validated by randomized, prospective clinical trials.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Li J, Fink JB, Augustynovich AE, et al. Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia. Crit Care Explor. 2020. PMID: 33354678. doi:10.1097/CCE.0000000000000307

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。